{"title":"Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib.","authors":"David Fidler, Karen A Gelmon, Christine Simmons","doi":"10.1080/14796694.2025.2529151","DOIUrl":null,"url":null,"abstract":"<p><p>Tucatinib has significantly advanced the treatment of HER2-positive metastatic breast cancer. When used in combination with trastuzumab and capecitabine, it improves survival for heavily pretreated patients, including patients with brain metastases. Its efficacy was demonstrated in the HER2CLIMB trial and it stands as an optimal choice for patients with brain metastases, a patient population who have historically been excluded from clinical trials. Tucatinib is orally administered and has a manageable safety profile. Common adverse events include diarrhea, nausea, fatigue, and liver enzyme elevations, which are typically manageable with dose modifications and supportive care. With strong clinical efficacy and widespread approval since 2020, tucatinib remains an important treatment option for patients with HER2-positive metastatic breast cancer.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2439-2449"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330270/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2529151","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Tucatinib has significantly advanced the treatment of HER2-positive metastatic breast cancer. When used in combination with trastuzumab and capecitabine, it improves survival for heavily pretreated patients, including patients with brain metastases. Its efficacy was demonstrated in the HER2CLIMB trial and it stands as an optimal choice for patients with brain metastases, a patient population who have historically been excluded from clinical trials. Tucatinib is orally administered and has a manageable safety profile. Common adverse events include diarrhea, nausea, fatigue, and liver enzyme elevations, which are typically manageable with dose modifications and supportive care. With strong clinical efficacy and widespread approval since 2020, tucatinib remains an important treatment option for patients with HER2-positive metastatic breast cancer.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
